SCHEMBL5503239

SCHEMBL5503239

CCOC(C#CC(=O)OC)OCC

nearest known ligand 0.30

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
MGAM O43451 1/20 0.30
GAA P10253 1/20 0.30
SI P14410 1/20 0.30
MGAM2 Q2M2H8 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4132648 0.83 ALDH1A1 (0.37) MGAMGAASIMGAM2
SCHEMBL3228082 0.78 THRB (0.32)
SCHEMBL12272261 0.78 SOAT1 (0.32)
SCHEMBL5047600 0.78 LMNA (0.33)
SCHEMBL12271661 0.75 LMNA (0.33)
SCHEMBL12272631 0.73
SCHEMBL1495932 0.72 CA1 (0.31)
SCHEMBL5045856 0.72 ACACB (0.31)
SCHEMBL5049024 0.71 ACACB (0.30)
SCHEMBL2955397 0.70

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5466830-A Preparation from a phenol and 4-dialkoxy-2-butynoic acid ester AMERICAN HOME PRODUCTS CORPORATION (US) 1995-11-14 US claimed
US-20160114057-A1 MODULAR PROTEIN DRUG CONJUGATE THERAPEUTIC ZYEWORKS INC. (CA) 2016-04-28 US disclosed
CN-101237892-A Method for conjugating molecules containing an aminothiol to a carrier AMGEN INC (US) 2008-08-06 CN disclosed
EP-1848463-A2 METHOD OF CONJUGATING AMINOTHIOL CONTAINING MOLECULES TO VEHICLES Amgen Inc. (US) 2007-10-31 EP disclosed
US-20060199812-A1 Method of conjugating aminothiol containing molecules to vehicles AMGEN INC. 2006-09-07 US disclosed
WO-2006079099-A2 METHOD OF CONJUGATING AMINOTHIOL CONTAINING MOLECULES TO A POLYMER AMGEN INC. (US) 2006-07-27 WO disclosed
EP-0918757-A1 8-HYDROCARBYL SUBSTITUTED BENZODIZOCINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS PROTEIN KINASE C (=PKC) MODULATORS GEORGETOWN UNIVERSITY (US) 1999-06-02 EP disclosed
WO-1997043268-A1 8-HYDROCARBYL SUBSTITUTED BENZODIZOCINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS PROTEIN KINASE C (=PKC) MODULATORS GEORGETOWN UNIVERSITY (US) 1997-11-20 WO disclosed
US-5466830-A Preparation from a phenol and 4-dialkoxy-2-butynoic acid ester AMERICAN HOME PRODUCTS CORPORATION (US) 1995-11-14 US disclosed
US-5336687-A For treating osteoporosis AMERICAN HOME PRODUCTS CORPORATION (US) 1994-08-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160114057-A1 MODULAR PROTEIN DRUG CONJUGATE THERAPEUTIC FCGRT, BCR, ERBB3 MGAM 859/4885GAA 579/4885SI 3509/4885
US-20060199812-A1 Method of conjugating aminothiol containing molecules to vehicles SLC7A1, QPCT, SLC7A5 MGAM 2863/4885GAA 2174/4885SI 774/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.